title: Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study.
abstract: The purpose of this phase I clinical trial was to evaluate the safety, tolerability and potential efficacy of VM202, naked DNA expressing two isoforms of hepatocyte growth factor, as an adjunct therapy to coronary artery bypass grafting (CABG) in patients with ischemic heart disease (IHD). Nine patients were assigned to receive increasing doses (0.5 to 2.0 mg) of VM202 injected into the right coronary artery (RCA) territory following completion of CABG for the left coronary artery territory. Patients were evaluated for safety and tolerability, and changes in myocardial functions were monitored via echocardiography, cardiac magnetic resonance imaging and myocardial single photon emission computed tomography throughout 6-month follow-up period. No serious complication related to VM202 was observed throughout the 6-month follow-up period. Global myocardial functions (wall motion score index, P=0.0084; stress perfusion, P=0.0002) improved during the follow-up period. In the RCA region, there was an increase in the stress perfusion (baseline vs 3-month, P=0.024; baseline vs 6-month, P=0.024) and also in the wall thickness of the diastolic and systolic phases. Intramyocardial injection of VM202 can be safely used in IHD patients with the tolerable dose of 2.0 mg. In addition, VM202 might appear to have improved regional myocardial perfusion and wall thickness in the injected region.
authors.affiliation: Seoul National University Bundang Hospital, Gyeonggi, Korea.
authors.forename: J S
authors.initials: JS
authors.lastname: Kim
authors.forename: H Y
authors.initials: HY
authors.lastname: Hwang
authors.forename: K R
authors.initials: KR
authors.lastname: Cho
authors.forename: E-A
authors.initials: EA
authors.lastname: Park
authors.forename: W
authors.initials: W
authors.lastname: Lee
authors.forename: J C
authors.initials: JC
authors.lastname: Paeng
authors.forename: D S
authors.initials: DS
authors.lastname: Lee
authors.forename: H-K
authors.initials: HK
authors.lastname: Kim
authors.forename: D-W
authors.initials: DW
authors.lastname: Sohn
authors.forename: K-B
authors.initials: KB
authors.lastname: Kim
mesh_terms: D000368:Aged; D001026:Coronary Artery Bypass; D005260:Female; D018014:Gene Transfer Techniques; D006321:Heart / Q000000981:diagnostic imaging* / Q000503:physiopathology; D017228:Hepatocyte Growth Factor / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000235:genetics / Q000601:surgery / Q000628:therapy*; D009206:Myocardium; D018919:Neovascularization, Physiologic / Q000235:genetics; D011859:Radiography; D015899:Tomography, Emission-Computed, Single-Photon; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000235:genetics
chemical_list: D019444:Vaccines, DNA; D017228:Hepatocyte Growth Factor